Bicara Therapeutics CEO Sells Shares Amid Strong Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: NASDAQ.COM
- Executive Stock Sale: Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares on May 18, 2026, for approximately $301,000, based on a weighted average price of $20.04 per share, representing 3.98% of her direct holdings prior to the transaction.
- Ownership Status: Post-transaction, Mazumdar retains 362,152 shares and over 146,000 stock options, indicating her substantial equity stake and ongoing confidence in the company's future.
- Compliance with Trading Plan: The stock sale was executed under a pre-arranged Rule 10b5-1 trading plan established in February 2025, which helps mitigate concerns about insider trading, suggesting that the transaction was non-discretionary and reducing investor anxiety.
- Financial Position: Despite a net loss of $56.2 million in Q1 2026, Bicara Therapeutics holds $539.8 million in cash and marketable securities, which is expected to fund operations through 2029, reflecting a solid financial foundation for ongoing research and development efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCAX
Wall Street analysts forecast BCAX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 21.950
Low
11.00
Averages
30.80
High
48.00
Current: 21.950
Low
11.00
Averages
30.80
High
48.00
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bicara Therapeutics CEO Sells Shares Amid Strong Performance
- Executive Stock Sale: Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares on May 18, 2026, for approximately $301,000, based on a weighted average price of $20.04 per share, representing 3.98% of her direct holdings prior to the transaction.
- Ownership Status: Post-transaction, Mazumdar retains 362,152 shares and over 146,000 stock options, indicating her substantial equity stake and ongoing confidence in the company's future.
- Compliance with Trading Plan: The stock sale was executed under a pre-arranged Rule 10b5-1 trading plan established in February 2025, which helps mitigate concerns about insider trading, suggesting that the transaction was non-discretionary and reducing investor anxiety.
- Financial Position: Despite a net loss of $56.2 million in Q1 2026, Bicara Therapeutics holds $539.8 million in cash and marketable securities, which is expected to fund operations through 2029, reflecting a solid financial foundation for ongoing research and development efforts.
See More
Bicara Therapeutics CEO Sells 15,000 Shares
- Transaction Overview: Bicara Therapeutics CEO Claire Mazumdar exercised 15,000 stock options and sold them immediately on May 18, 2026, generating $301,000, indicating her focus on liquidity amidst ongoing operational challenges.
- Shareholding Analysis: This transaction reduced Mazumdar's direct equity holdings by 4%, yet she retains 362,152 shares, highlighting her continued substantial economic alignment with the company and support for its long-term growth.
- Market Performance and Financial Status: Despite a net loss of $56.2 million in Q1 2026, Bicara Therapeutics boasts a market capitalization of $1.43 billion, with shares reaching a 52-week high of $24.25 in April, reflecting positive investor sentiment driven by favorable clinical trial results.
- Investor Considerations: Mazumdar's stock sale was part of a pre-arranged Rule 10b5-1 trading plan established in February 2025, indicating that her actions were not based on insider information, and she still holds over 146,000 options, suggesting confidence in the company's future prospects.
See More
Bicara Therapeutics CEO Sells Stock Options Amid Strong Performance
- Stock Option Exercise: Bicara Therapeutics CEO Claire Mazumdar exercised 15,000 stock options and sold them immediately on May 18, 2026, generating a transaction value of $301,000, indicating her need for liquidity amidst ongoing operational demands.
- Shareholding Changes: This transaction reduced Mazumdar's direct equity holdings by 4%, yet she retains 362,152 shares, reflecting continued substantial economic alignment with the company despite the decrease in her holdings.
- Transaction Context: The stock sale was part of a pre-arranged Rule 10b5-1 trading plan established in February 2025, aimed at avoiding insider trading accusations, suggesting that the transaction was non-discretionary and unlikely to raise investor concerns.
- Financial Position: Despite a net loss of $56.2 million in Q1, Bicara reported $539.8 million in cash and equivalents at the end of the quarter, which is expected to fund operations through 2029, highlighting its ongoing commitment to R&D and potential future growth.
See More
Bicara Therapeutics Reports New Data Showing Ficerafusp Alfa Significantly Improves Survival Rates
- Significant Survival Improvement: At a three-year follow-up, the combination of 1500mg ficerafusp alfa with pembrolizumab demonstrated an overall survival rate of 31%, nearly doubling the rate observed with standard treatment, highlighting the therapy's potential in 1L R/M HPV-negative head and neck squamous cell carcinoma.
- Durable Responses and Tolerability: Across all dose cohorts, the combination therapy achieved an 80% deep response rate with a generally well-tolerated safety profile and no new safety signals, indicating its feasibility for clinical application.
- Clinical Data Validation: The complete response rates were 13%, 25%, and 30% for the 750mg, 1500mg, and 2000mg cohorts respectively, demonstrating a significant increase in efficacy with higher doses, further solidifying ficerafusp alfa's best-in-class status.
- Future Research Plans: Bicara plans to initiate a new study in Q3 2026 to evaluate a 12-week loading dose followed by a 2250mg every-three-weeks maintenance regimen, showcasing the company's ongoing investment and confidence in the therapy's long-term effectiveness.
See More
Omega Fund Increases Stake in Bicara Therapeutics
- Share Acquisition: Omega Fund disclosed a purchase of 187,500 shares of Bicara Therapeutics in an SEC filing dated May 15, 2026, with an estimated transaction value of $3.23 million, indicating strong confidence in the company's prospects.
- Asset Allocation Shift: This acquisition raised Bicara's position to 29.16% of Omega Fund's reported assets, reflecting a highly concentrated investment strategy in the biotech sector that may influence future investment decisions.
- Financial Overview: As of March 2026, Bicara reported $539.8 million in cash and marketable securities, sufficient to fund operations into the first half of 2029, despite a widening quarterly net loss of $56.2 million due to increased R&D spending.
- Clinical Progress: Bicara is advancing its experimental therapy ficerafusp alfa for head and neck cancer, with management expecting substantial enrollment in the pivotal Phase 2/3 FORTIFI-HN01 study by year-end, showcasing its potential in oncology treatment.
See More
Bicara Therapeutics Appoints New CCO and Grants Stock Options
- Executive Appointment: Bicara Therapeutics appointed Christopher Sarchi as Chief Commercial Officer effective May 8, 2026, granting him 282,240 stock options at an exercise price of $22.58 per share, reflecting the company's confidence in his potential to drive future performance.
- Stock Option Structure: Sarchi's stock options will vest one-fourth on the first anniversary of his start date, with the remaining shares vesting in 12 equal quarterly installments, designed to incentivize his long-term commitment and alignment with the company's commercial objectives.
- Independent Board Approval: The stock option grant was approved by Bicara's compensation committee, which consists solely of independent directors, ensuring transparency and compliance with Nasdaq Listing Rule 5635(c)(4), thereby reinforcing corporate governance standards.
- Therapeutic Platform Development: Bicara is focused on developing bifunctional therapies, particularly its lead program ficerafusp alfa, which aims to enhance anti-tumor activity by simultaneously targeting EGFR and TGF-β, addressing significant unmet needs in solid tumors like head and neck squamous cell carcinoma.
See More
Bicara Therapeutics CEO Sells Shares Amid Strong Performance
- Executive Stock Sale: Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares on May 18, 2026, for approximately $301,000, based on a weighted average price of $20.04 per share, representing 3.98% of her direct holdings prior to the transaction.
- Ownership Status: Post-transaction, Mazumdar retains 362,152 shares and over 146,000 stock options, indicating her substantial equity stake and ongoing confidence in the company's future.
- Compliance with Trading Plan: The stock sale was executed under a pre-arranged Rule 10b5-1 trading plan established in February 2025, which helps mitigate concerns about insider trading, suggesting that the transaction was non-discretionary and reducing investor anxiety.
- Financial Position: Despite a net loss of $56.2 million in Q1 2026, Bicara Therapeutics holds $539.8 million in cash and marketable securities, which is expected to fund operations through 2029, reflecting a solid financial foundation for ongoing research and development efforts.
See More
Bicara Therapeutics CEO Sells 15,000 Shares
- Transaction Overview: Bicara Therapeutics CEO Claire Mazumdar exercised 15,000 stock options and sold them immediately on May 18, 2026, generating $301,000, indicating her focus on liquidity amidst ongoing operational challenges.
- Shareholding Analysis: This transaction reduced Mazumdar's direct equity holdings by 4%, yet she retains 362,152 shares, highlighting her continued substantial economic alignment with the company and support for its long-term growth.
- Market Performance and Financial Status: Despite a net loss of $56.2 million in Q1 2026, Bicara Therapeutics boasts a market capitalization of $1.43 billion, with shares reaching a 52-week high of $24.25 in April, reflecting positive investor sentiment driven by favorable clinical trial results.
- Investor Considerations: Mazumdar's stock sale was part of a pre-arranged Rule 10b5-1 trading plan established in February 2025, indicating that her actions were not based on insider information, and she still holds over 146,000 options, suggesting confidence in the company's future prospects.
See More
Bicara Therapeutics CEO Sells Stock Options Amid Strong Performance
- Stock Option Exercise: Bicara Therapeutics CEO Claire Mazumdar exercised 15,000 stock options and sold them immediately on May 18, 2026, generating a transaction value of $301,000, indicating her need for liquidity amidst ongoing operational demands.
- Shareholding Changes: This transaction reduced Mazumdar's direct equity holdings by 4%, yet she retains 362,152 shares, reflecting continued substantial economic alignment with the company despite the decrease in her holdings.
- Transaction Context: The stock sale was part of a pre-arranged Rule 10b5-1 trading plan established in February 2025, aimed at avoiding insider trading accusations, suggesting that the transaction was non-discretionary and unlikely to raise investor concerns.
- Financial Position: Despite a net loss of $56.2 million in Q1, Bicara reported $539.8 million in cash and equivalents at the end of the quarter, which is expected to fund operations through 2029, highlighting its ongoing commitment to R&D and potential future growth.
See More
Bicara Therapeutics Reports New Data Showing Ficerafusp Alfa Significantly Improves Survival Rates
- Significant Survival Improvement: At a three-year follow-up, the combination of 1500mg ficerafusp alfa with pembrolizumab demonstrated an overall survival rate of 31%, nearly doubling the rate observed with standard treatment, highlighting the therapy's potential in 1L R/M HPV-negative head and neck squamous cell carcinoma.
- Durable Responses and Tolerability: Across all dose cohorts, the combination therapy achieved an 80% deep response rate with a generally well-tolerated safety profile and no new safety signals, indicating its feasibility for clinical application.
- Clinical Data Validation: The complete response rates were 13%, 25%, and 30% for the 750mg, 1500mg, and 2000mg cohorts respectively, demonstrating a significant increase in efficacy with higher doses, further solidifying ficerafusp alfa's best-in-class status.
- Future Research Plans: Bicara plans to initiate a new study in Q3 2026 to evaluate a 12-week loading dose followed by a 2250mg every-three-weeks maintenance regimen, showcasing the company's ongoing investment and confidence in the therapy's long-term effectiveness.
See More
Omega Fund Increases Stake in Bicara Therapeutics
- Share Acquisition: Omega Fund disclosed a purchase of 187,500 shares of Bicara Therapeutics in an SEC filing dated May 15, 2026, with an estimated transaction value of $3.23 million, indicating strong confidence in the company's prospects.
- Asset Allocation Shift: This acquisition raised Bicara's position to 29.16% of Omega Fund's reported assets, reflecting a highly concentrated investment strategy in the biotech sector that may influence future investment decisions.
- Financial Overview: As of March 2026, Bicara reported $539.8 million in cash and marketable securities, sufficient to fund operations into the first half of 2029, despite a widening quarterly net loss of $56.2 million due to increased R&D spending.
- Clinical Progress: Bicara is advancing its experimental therapy ficerafusp alfa for head and neck cancer, with management expecting substantial enrollment in the pivotal Phase 2/3 FORTIFI-HN01 study by year-end, showcasing its potential in oncology treatment.
See More
Bicara Therapeutics Appoints New CCO and Grants Stock Options
- Executive Appointment: Bicara Therapeutics appointed Christopher Sarchi as Chief Commercial Officer effective May 8, 2026, granting him 282,240 stock options at an exercise price of $22.58 per share, reflecting the company's confidence in his potential to drive future performance.
- Stock Option Structure: Sarchi's stock options will vest one-fourth on the first anniversary of his start date, with the remaining shares vesting in 12 equal quarterly installments, designed to incentivize his long-term commitment and alignment with the company's commercial objectives.
- Independent Board Approval: The stock option grant was approved by Bicara's compensation committee, which consists solely of independent directors, ensuring transparency and compliance with Nasdaq Listing Rule 5635(c)(4), thereby reinforcing corporate governance standards.
- Therapeutic Platform Development: Bicara is focused on developing bifunctional therapies, particularly its lead program ficerafusp alfa, which aims to enhance anti-tumor activity by simultaneously targeting EGFR and TGF-β, addressing significant unmet needs in solid tumors like head and neck squamous cell carcinoma.
See More
